Compare CRMT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | SGHT |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 187.4M |
| IPO Year | 2026 | 2021 |
| Metric | CRMT | SGHT |
|---|---|---|
| Price | $12.17 | $4.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $29.50 | $9.08 |
| AVG Volume (30 Days) | 116.4K | ★ 359.9K |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | $4.92 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.58 | $2.74 |
| 52 Week High | $62.55 | $9.24 |
| Indicator | CRMT | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 59.53 |
| Support Level | $10.81 | $3.30 |
| Resistance Level | $13.63 | $5.32 |
| Average True Range (ATR) | 1.01 | 0.26 |
| MACD | 0.36 | 0.12 |
| Stochastic Oscillator | 42.57 | 54.50 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.